Scroll
To Top

Archives for: July 9th, 2018

Public Meeting on Patient-Focused Drug Development for Chronic Pain

Written by Christina Jensen on July 9, 2018

On July 9, 2018, FDA is hosting a public meeting on Patient-Focused Drug Development for Chronic Pain. FDA is interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA is particularly interested in hearing from patients who… Read More

NORD Issues Statement on Recent CMS Actions Pertaining to Patient Access Within Medicaid Formularies

Written by Christina Jensen on June 27, 2018
Washington, D.C., June 27, 2018 – The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, released the following statement regarding this week’s actions by the Centers for Medicare and Medicaid Services (CMS) to protect patient access to medication… Read More

NORD Issues Statement Regarding House Passage of the Right to Try Act (S.204)

Written by Christina Jensen on May 22, 2018
Washington, D.C., May 22, 2018 – The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, issued the following statement following today’s passage of the Right to Try Act (S.204) in the House of Representatives:
“Today, the House of Representatives passed the… Read More

Richard Pazdur, M.D.: 2018 Public Health Leadership Award Honoree

Written by Christina Jensen on April 25, 2018

Richard Pazdur, M.D. is the Director of the Food and Drug Administration’s Oncology Center of Excellence (OCE), which leverages the combined skills of the FDA’s regulatory scientists and reviewers with expertise in drugs, biologics and devices to expedite the development of novel cancer products. In his role as director of… Read More